Lonza Biologics, Inc.

Form 483 issued March 7, 2024 · Portsmouth, New Hampshire

Inspection
Mar 7, 2024
Observations
2
Pages
4
FEI number
3001451441

In short: On March 7, 2024, FDA issued a Form 483 with 2 observations to Lonza Biologics, Inc. in Portsmouth, New Hampshire (FEI 3001451441) after an inspection that ran Mar 7, 2024. The investigators were Lewis K. Antwi, Priscilla M. Pastrana, Svetlana A. Shestopal and Vijaya Simhadri. Most observations concern quality system and production; the most-cited regulation is 21 CFR 211.192 (production record review).

At a glance

Quality system and production account for 2 of 2 observations.

Quality system1
Production1

Most cited: 21 CFR 211.192 (1×) · 211.100 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Failure to conduct investigations…

  2. 02

    Failure to follow established…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Lonza Biologics, Inc.?

FDA listed 2 observations on this Form 483, mostly about quality system and production. The most-cited regulation is 21 CFR 211.192 (production record review). The opening words of each observation are shown on this page.

Who inspected Lonza Biologics, Inc.?

Lewis K. Antwi, Priscilla M. Pastrana, Svetlana A. Shestopal and Vijaya Simhadri are named on this Form 483, for the inspection of Mar 7, 2024. Each investigator has a profile showing what they cite most.

When was Lonza Biologics, Inc. inspected by FDA?

The inspection ran Mar 7, 2024, and the Form 483 is dated March 7, 2024.

How do I get the full Form 483 for Lonza Biologics, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free